Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas

NCT04672005 is registered in ClinicalTrials.gov with Lyudmyla Berim as lead sponsor.

NCT NCT04672005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04672005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
Lyudmyla Berim
Phase
Phase 2
Overall status
Unknown status
Start date
January 6, 2021
Completion date
June 1, 2025
Enrollment
30 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer